Bausch Health Companies (BHC) Total Non-Current Liabilities (2009 - 2026)
Bausch Health Companies' (BHC) quarterly Total Non-Current Liabilities came in at $24.8 billion in Q1 2026, down 4.18% year-on-year from $25.9 billion in Q1 2025, and down 1.5% quarter-over-quarter from $25.2 billion in Q4 2025.
Bausch Health Companies (BHC) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Bausch Health Companies has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $24.8 billion for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $24.8 billion, down 4.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.8 billion (down 4.18% YoY), and the FY2025 annual result was $25.2 billion, down 3.58% from the prior year.
- Total Non-Current Liabilities came in at $24.8 billion for Q1 2026 at Bausch Health Companies, down from $25.2 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $28.7 billion in Q1 2022 to a low of $24.5 billion in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $26.0 billion (2024), against an average of $25.9 billion.
- Peak annual rise in Total Non-Current Liabilities reached 7.98% in 2023, while the deepest fall reached 14.41% in 2023.
- Bausch Health Companies' Total Non-Current Liabilities stood at $24.7 billion in 2022, then rose by 7.98% to $26.7 billion in 2023, then slipped by 1.97% to $26.1 billion in 2024, then dropped by 3.58% to $25.2 billion in 2025, then decreased by 1.5% to $24.8 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $24.8 billion (Q1 2026), $25.2 billion (Q4 2025), and $25.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Bausch Health Companies | 1.91 Bn | 1.58 Bn | 2.48 Bn | 24.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.82 Bn |
| Dec 31, 2025 | 25.20 Bn |
| Sep 30, 2025 | 25.63 Bn |
| Jun 30, 2025 | 26.24 Bn |
| Mar 31, 2025 | 25.90 Bn |
| Dec 31, 2024 | 26.13 Bn |
| Sep 30, 2024 | 25.98 Bn |
| Jun 30, 2024 | 25.98 Bn |
| Mar 31, 2024 | 26.34 Bn |
| Dec 31, 2023 | 26.66 Bn |
| Sep 30, 2023 | 26.58 Bn |
| Jun 30, 2023 | 24.49 Bn |
| Mar 31, 2023 | 24.55 Bn |
| Dec 31, 2022 | 24.69 Bn |
| Sep 30, 2022 | 25.25 Bn |
| Jun 30, 2022 | 27.39 Bn |
| Mar 31, 2022 | 28.69 Bn |
| Dec 31, 2021 | 28.58 Bn |
| Sep 30, 2021 | 28.52 Bn |
| Jun 30, 2021 | 29.68 Bn |